ArticleFrontiers in endocrinology2026
Clinical efficacy, safety, and predictors of treatment response to SGLT2 versus DPP-4 inhibitors in type 2 diabetes: a retrospective comparative study.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prevalence of type 2 diabetes is continuously increasing, and optimizing the treatment strategies for diabetes is an important clinical issue. SGLT2 inhibitors (SGLT2i) and DPP-4 inhibitors (DPP-4i) are two commonly used oral hypoglycemic drugs, and their comprehensive efficacy and safety profiles in real-world settings merit in-depth comparison. Objective: To compare the clinical efficacy and safety of SGLT2i and DPP-4i in treating patients with type 2 diabetes from May 2024 to August 2025, and to explore the predictive factors influencing treatment response. Method: A retrospective cohort study was conducted using medical records of 100 patients with type 2 diabetes who met standardized screening criteria. These patients were assigned to two treatment groups: the SGLT2 inhibitor group (SGLT2i, n=50) and the DPP-4 inhibitor group (DPP-4i, n=50). Primary endpoints comprised changes in glycated hemoglobin (HbA1c) levels and the occurrence of major adverse cardiovascular events. Secondary outcomes including changes in body mass index, blood pressure, renal function parameters (urinary albumin-to-creatinine ratio and estimated glomerular filtration rate), lipid profile, liver function markers, and the frequency of adverse events. Exploratory measures, including inflammatory markers such as C-reactive protein, were also evaluated. Statistical analyses were performed using SPSS, including t-tests, chi-square tests, and multivariate logistic regression. Results: Regarding primary outcomes, comparable reductions in HbA1c were observed in both groups. In terms of safety profiles, the SGLT2i group exhibited a significantly lower rate of major adverse cardiovascular events compared to the DPP-4i group (2.00% vs. 16.00%, Conclusion: In patients with type 2 diabetes, SGLT2i and DPP-4i have comparable hypoglycemic efficacy, but SGLT2i shows additional advantages in weight loss, reduction in blood pressure, and improvement in renal outcomes. Baseline characteristics of patients may serve as useful references for individualized treatment choices.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.